Bactana develops therapies for pets to treat prediabetes, diabetes and products to reduce antibiotic use during livestock production.
Bactana Corp. has raised $400K in total funding. The most recent round was Debt Financing. The last funding was announced in July 2022.
Bactana Corp.'s investors include Connecticut Innovations, National Science Foundation, Cornell University, Propel, Sustainable Income Capital Management.
Bactana Corp. is headquartered in Farmington, United States.
Bactana develops therapies for pets to treat prediabetes, diabetes and products to reduce antibiotic use during livestock production.
Bactana Corp. is at the Debt Financing stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Bactana Corp. — Funding & Investors." VCBacked, July 7, 2022, https://www.vcbacked.co/company/bactana-corp. Accessed November 12, 2026.
VCBacked. (2022). Bactana Corp. — Funding & Investors. Retrieved November 12, 2026, from https://www.vcbacked.co/company/bactana-corp
{{cite web |title=Bactana Corp. — Funding & Investors |url=https://www.vcbacked.co/company/bactana-corp |website=VCBacked |access-date=November 12, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at Bactana Corp.? Request a listing update